RVL Pharmaceuticals Announces New CEO, Chief Growth Officer

RVL Pharmaceuticals, Inc. has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer, signaling a strategic leadership shift aimed at accelerating growth for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Deo, who previously served as Executive Chairwoman of the Board, brings experience from Johnson & Johnson and Pfizer, where she helped scale healthcare and beauty brands. Her promotion follows a transition of the Chairperson role to affiliates of Athyrium Capital Management, LP, RVL’s majority shareholder.

Shah, also a Johnson & Johnson alum, will now lead RVL’s integrated commercial organization, overseeing sales, marketing, innovation, and pipeline development. Her expanded role aligns with the company’s intent to reshape engagement models and drive brand momentum.

“RVL is entering a pivotal next phase of growth,” said Deo. “These leadership appointments strengthen our ability to scale, deepen engagement with consumers and healthcare providers, and fully capitalize on the category-defining potential of Upneeq, with an estimated $2.5B Total Addressable Market (TAM). We are committed to investing with intention to unlock TAM, build and scale a new category, and accelerate brand and platform momentum.”